Key opinion leaders in the fields of exosomes, liquid biopsy and liver disease support Mursla’s ambition

Mursla has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes.

Mursla has raised additional funding from the UK Government’s Future Fund and existing investors.

Mursla is dedicating resources to help improve COVID-19 diagnostics & therapeutics solutions. We are currently capitalising upon our...

Mursla was selected again as one of the most exciting tech companies to follow in the Cambridge cluster. https://www.cambridgeindependent...

It will be a great opportunity for Mursla to explain the value of its new platform technology to the general public. Final will take...

We are delighted to have won the #onetowatch award as one of the most innovative companies in Cambridgeshire and East of England. The...